

RECEIVED
CENTRAL FAX CENTER

NOV 18 2005

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

November 18, 2005

FACSIMILE TRANSMISSION SHEET

TO Examiner Daniel Kolker
COMPANY U.S. Patent &
Trademark Office
FAX NO. 571-273-8300
PHONE NO.

FROM: Katherine L. Neville

EXTENSION: 300

PAGES (INCLUDING THIS PAGE): 9

CLIENT NO: 30610

MATTER NO: 39383

PLEASE CONFIRM RECEIPT: yes

COUNTRY CODE: US

MESSAGE:

Please contact Mary Vlasak at (312) 474-6300 if you do not receive all of the pages in good condition.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

RECEIVED
CENTRAL FAX CENTER

NOV 18 2005

I hereby certify that this correspondence is being facsimile transmitted to telephone no. (571) 273-8300, addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 18, 2005

Signature: *Katherine L. Neville*

Katherine L. Neville

**EXPEDITED PROCEDURE
RESPONSE AFTER FINAL**

ART UNIT 1646

Docket No.: 30610/39383

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Zankel et al.

Application No.: 10/600,862

Filed: June 20, 2003

Art Unit: 1646

For: USE OF THE CHAPERONE RECEPTOR
ASSOCIATED PROTEIN (RAP) FOR THE
DELIVERY OF THERAPEUTIC
COMPOUNDS TO THE BRAIN AND OTHER
TISSUES

Examiner: Daniel Kolker

RESPONSE TO FINAL OFFICE ACTION DATED SEP. 16, 2005

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This paper is filed in response to a final Office Action dated September 16, 2005 in which the Examiner maintained the rejections of claims 14 and 17-24 under 35 U.S.C. §§ 112 and 103. Reconsideration is respectfully requested in light of the following amendments and remarks. This paper is believed timely filed; if necessary, however, please charge any deficiency in fees to our Deposit Account No. 13-2855.

Amendments to the claims are reflected in the complete listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.